ArticleJournal of pain research2010
Milnacipran for the management of fibromyalgia syndrome.
Article in Journal of pain research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 5 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Flexibility exercise training for adults with fibromyalgia.The Cochrane database of systematic reviews · 2019Pooled it
- Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.The Cochrane database of systematic reviews · 2018Pooled it
- A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.Drugs in R&D · 2017Pooled it
- Milnacipran for pain in fibromyalgia in adults.The Cochrane database of systematic reviews · 2015Pooled it
- Milnacipran for neuropathic pain and fibromyalgia in adults.The Cochrane database of systematic reviews · 2012Pooled it
- Effect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial.The Journal of rheumatology · 2016Trial
- Trial
- A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Trial
- Systemic and Brain Pharmacokinetics of Milnacipran in Mice: Comparison of Intraperitoneal and Intravenous Administration.Pharmaceutics · 2023Article
- Pharmacological treatments of fibromyalgia in adults; overview of phase IV clinical trials.Frontiers in pharmacology · 2022Review
- Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology.Biomedicines · 2017Review
- Coadministration of Resveratrol and Rice Oil Mitigates Nociception and Oxidative State in a Mouse Fibromyalgia-Like Model.Pain research and treatment · 2016Article
- Monotherapy or combination therapy for fibromyalgia treatment?Current rheumatology reports · 2012Review
- Usefulness of milnacipran in treating phantom limb pain.Neuropsychiatric disease and treatment · 2012Article
- The FIBRO System: A Rapid Strategy for Assessment and Management of Fibromyalgia Syndrome.Therapeutic advances in musculoskeletal disease · 2010Article
- Pregabalin for the management of fibromyalgia syndrome.Journal of pain research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibromyalgia syndrome (FMS) is a widespread pain condition associated with fatigue, cognitive dysfunction, sleep disturbance, depression, anxiety, and stiffness. Milnacipran is one of three medications currently approved by the Food and Drug Administration in the United States for the management of adult FMS patients. This review is the second in a three-part series reviewing each of the approved FMS drugs and serves as a primer on the use of milnacipran in FMS treatment including information on pharmacology, pharmacokinetics, safety and tolerability. Milnacipran is a mixed serotonin and norepinephrine reuptake inhibitor thought to improve FMS symptoms by increasing neurotransmitter levels in descending central nervous system inhibitory pathways. Milnacipran has proven efficacy in managing global FMS symptoms and pain as well as improving symptoms of fatigue and cognitive dysfunction without affecting sleep. Due to its antidepressant activity, milnacipran can also be beneficial to FMS patients with coexisting depression. However, side effects can limit milnacipran tolerability in FMS patients due to its association with headache, nausea, tachycardia, hyper- and hypotension, and increased risk for bleeding and suicidality in at-risk patients. Tolerability can be maximized by starting at low dose and slowly up-titrating if needed. As with all medications used in FMS management, milnacipran works best when used as part of an individualized treatment regimen that includes resistance and aerobic exercise, patient education and behavioral therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.